Recently, the combination of osimertinib, an ATP-binding competitive inhibitor of epidermal growth factor receptor (EGFR), with EGFR allosteric inhibitors was reported as a next-generation lung cancer therapeutic strategy [26]. This evidence concerns the gene EGFR and lung carcinoma.